



OPEN Mitochondrial function in patients affected with fibromyalgia syndrome is impaired and correlates with disease severity

Chiara Macchi¹, Andrea Giachi², Isabella Fichtner¹, Silvia Pedretti¹, Piercarlo Sarzi Puttini^{3,4}, Nico Mitro^{1,5}, Alberto Corsini¹, Massimiliano Ruscica^{1,6,8}✉ & Roberta Gualtierotti^{2,7,8}✉

Fibromyalgia is a musculoskeletal syndrome characterized by chronic widespread pain that is often associated with systemic manifestations. Since mitochondria are the main source of cellular energy, we hypothesized that fibromyalgia syndrome (FMS) could be linked to mitochondrial impairment. Aim was to study mitochondrial dysfunction in peripheral blood mononuclear cells isolated from 50 patients with primary FMS and 20 apparently healthy controls. Although no differences in mitochondrial basal respiration were observed between patients with primary FMS and healthy controls, a lower median bioenergetic health index (BHI; -22.1% , $p=0.03$), a proxy of mitochondrial function, was found in patients. According to fibromyalgia severity score (FSS), a composite of widespread pain index and symptom severity scale, a lower median BHI (-18.7%) was found in patients with a $FSS \geq 20$ compared to those with a $FSS < 20$. Negative moderate correlations were found only between BHI and FSS ($r = -0.36$) and widespread pain index ($r = -0.38$). We demonstrated that patients with FMS had an impaired mitochondrial function. Additionally, we found a mild correlation between the widespread pain index and the BHI, possibly indicating that the altered mitochondrial function, in these patients, narrows musculoskeletal rather than central nervous system involvement.

Fibromyalgia, a musculoskeletal syndrome, is characterized by chronic widespread pain that is often accompanied by systemic manifestations, such as persistent fatigue, sleep disturbance and cognitive impairment, hyperalgesia and allodynia¹. These symptoms significantly impact health-related quality of life. Initially, diagnostic criteria were based on tender points on the body, as defined by the American College of Rheumatology (ACR)². However, the criteria have since shifted to include a more complex set of features including both the widespread nature of pain and associated symptoms³. Fibromyalgia syndrome (FMS) has a prevalence of 2–8% in the general population and it can develop at any age, including childhood, with higher frequency in females^{4–6}.

Despite significantly impacting quality of life, FMS remains an under-diagnosed disease⁷. The pathogenic mechanisms and the underlying reason for fibromyalgia-related changes are not fully understood, leading to a lack of specific biomarkers⁸. Research suggests that it may be related to abnormalities in the central nervous system and immune system, as well as to genetic and environmental factors⁹. Initially perceived primarily as a rheumatic disorder, it is now recognized as a disorder involving pain processing and central nervous system sensitization^{10,11}.

One theory proposed, as a potential contributor to FMS, involves the dysfunction of mitochondria, which are the energy-producing organelles within our cells and serve as the primary source of cellular energy. When mitochondria malfunction, it can lead to reduced adenosine triphosphate (ATP) production, increased oxidative stress, disrupted calcium homeostasis, and altered mitochondrial membrane potential. These impairments can affect metabolism, cell death and inflammation pathways, innate immune responses, potentially contributing to the pathogenesis of several diseases¹².

¹Department of Pharmacological and Biomolecular Sciences “Rodolfo Paoletti”, Università Degli Studi di Milano, Milan, Italy. ²Department of Pathophysiology and Transplantation, Università Degli Studi di Milano, Milan, Italy. ³Rheumatology Department, IRCCS Galeazzi-S. Ambrogio Hospital, Milan, Italy. ⁴Department of Biomedical and Clinical Sciences, Università Degli Studi di Milano, Milan, Italy. ⁵Department of Experimental Oncology, IEO, European Institute of Oncology IRCCS, Milan, Italy. ⁶Department of Cardio-Thoracic-Vascular Diseases, Foundation IRCCS Cà Granda Ospedale Maggiore Policlinico, Milan, Italy. ⁷Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, S.C. Medicina – Emostasi e Trombosi, Milan, Italy. ⁸These authors have contributed equally: Massimiliano Ruscica and Roberta Gualtierotti. ✉email: massimiliano.ruscica@unimi.it; roberta.gualtierotti@unimi.it

In the context of FMS pathogenesis, the relevance of mitochondrial dysfunction has been highlighted in a reserpine-induced fibromyalgia rodent model. These animals exhibited reduced functionality of mitochondrial complexes I and II, decreased electron transport, impaired mitochondrial respiration, reduced mitochondrial biogenesis, and altered mitochondrial dynamic. Additionally, they experienced lower ATP synthesis in muscles and spinal cord^{13,14}. Furthermore, individuals with FMS could show decreased ATP production in their muscle cells, contributing to muscle fatigue and overall fatigue experienced by fibromyalgia patients¹⁵. While measuring skeletal muscle mitochondrial respiration typically requires an invasive muscle biopsy, polymorphonucleate cells (PBMC) can offer a less invasive alternative for assessing muscle mitochondrial function. PBMCs are crucial for maintaining organic balance and act as “sentinel tissues” to monitor the body’s responses¹⁶. PBMC mitochondrial function is a reliable biomarker for muscle mitochondrial function in pathological populations with varying respiration capacities¹⁷. Symptoms associated with FMS, such as fatigue, exercise intolerance, and myalgia, are common in primary mitochondrial diseases, usually resulting from mitochondrial dysfunction due to nuclear or mitochondrial DNA mutations¹⁸. An analysis of PBMCs from 7 FMS patients versus 7 controls revealed morphological changes in mitochondria of FMS patients, primarily a loss of mitochondrial cristae. These findings suggest that mitochondrial dysfunction may contribute to the chronic pain and fatigue seen in FMS¹⁹.

Building upon this context, our study was aimed to study the mitochondrial function in PBMC from patients with primary FMS and to establish correlations with the clinical phenotype.

Methods

Patients

Consecutive patients of all ages and sexes affected with primary FMS who were willing to participate in the study were included from June 2023 to January 2024 at the Fibromyalgia syndrome outpatient clinic of the S.C. Medicina—Emostasi e Trombosi at Fondazione IRCCS Ca’ Granda Ospedale Maggiore, Milano, Italy. FMS was defined based on the presence of the 2016 criteria³. Demographic data, smoke, comorbidities and current therapy were collected. Patients with a diagnosis of inflammatory or systemic autoimmune disease were excluded.

Study design and ethics committee approval

This is a cross-sectional study. Ethics committee approval was obtained by the Milan Area 2 Ethics Committee on 23rd May 2023 (approval n°310_2023). All patients provided written informed consent. The research was performed in accordance with the Declaration of Helsinki, and it adheres to relevant guidelines/regulations.

Fibromyalgia severity score

The fibromyalgia severity score (FSS) was used to classify the severity of patients³. The FSS is composed of two parts: the widespread pain index (WPI), which ranges between 0 and 19 and is a summary count of the number of 19 painful regions from the self-reported Regional Pain Scale (RPS)²⁰, and the symptom severity scale (SSS), which ranges between 0 and 12, and is the sum of the severity scores of 3 symptoms (fatigue, waking unrefreshed, and cognitive symptoms) [0–9] plus the sum [0–3] of the score of the following symptoms occurring during the previous 6 months: (1) headaches [0–1], (2) abdominal pain or cramps [0–1] and (3) depression [0–1].

The 2016 criteria envisage that the following three conditions are met: (a) WPI ≥ 7 and SSS score ≥ 5 OR WPI of 4–6 and SSS score ≥ 9 ; (b) generalized pain, defined as pain in at least 4 of 5 regions, with jaw, chest, and abdominal pain not included; (c) symptoms must be present for at least three months. In addition, a diagnosis of fibromyalgia syndrome is valid irrespective of other diagnoses and does not exclude the presence of other clinically important illnesses³.

Isolation of human PBMC

PBMCs were isolated by using Ficoll-Hypaque density gradient centrifugation (Merck, Milan, Italy). Briefly, blood was collected and centrifuged (15 min. at $2500 \times g$) to separate the plasma. The remaining blood was then diluted with RPMI-1640 medium and layered onto the Ficoll-Hypaque media solution. The subsequent density gradient centrifugation (40 min. at $400 \times g$) allowed to isolate PBMC.

Mitochondrial functionality assessment

Mitochondrial functionality was measured by means of the Seahorse XF Cell Mito Stress Test (Agilent, Santa Clara, USA), which measures key parameters of mitochondrial function by directly measuring the oxygen consumption rate (OCR) of cells^{21–23}. OCR was measured at baseline to determine basal respiration and after injection of optimized doses of specific mitochondrial activators and inhibitors to determine non-mitochondrial respiration, maximal respiration and spare respiratory capacity. This assay allows to obtain data relative to the reserve capacity, the ATP-linked mitochondrial respiration, the non-mitochondrial respiration and the proton leak. The spare respiratory capacity was calculated as a percentage, as follows: (maximal respiration/basal respiration) $\times 100$. PBMCs were seeded in a pre-coated sterile 24-well plate with a dedicated medium, at a density of 500,000 cells per well. OCR was recorded at the basal level and after the sequential injections of 1 μM Oligomycin (ATP synthase inhibitor), 1 μM Carbonyl cyanide-4 (trifluoromethoxy) phenylhydrazone (FCCP, uncoupling agent) and a mixture of 0.5 μM Rotenone (complex I inhibitor) and Antimycin A (complex III inhibitor)²⁴. OCR data were then normalized per protein concentration in each well. Protein concentration was determined by the Pierce BCA protein assay (Thermo Fisher Scientific, Milan, Italy).

Mitochondrial bioenergetic health index (BHI) calculation

To evaluate the Bioenergetic Health Index (BHI)²⁵ of each patient the OCRs of PBMCs, measured through the Seahorse XF Cell Mito Stress Test, were considered. The resulting indices of bioenergetic function were considered and the following formula was used:

$$\text{BHI} = \log \frac{\text{reserve capacity} \times \text{ATP} - \text{linked}}{\text{non} - \text{mitochondrial} \times \text{proton leak}}$$

Sample size calculation

Based on our preliminary data, we considered the presence of an altered OCR value in healthy controls of 20% and in FMS of 70%. We decided to enroll controls vs FMS patients with a 1:2 ratio because of the difficulty in finding healthy female volunteers due to the high prevalence of FMS in the general population. To obtain a 5% alpha error and an 80% power, the minimum sample size for the group of controls should be of 10 and the minimum sample size of FMS patients should be of 20. The sample size calculation was performed using the calculation formula reported in²⁶.

Statistical analysis

Continuous variables were described as median and interquartile range (IQR), correlation between variables was calculated via Spearman's rho, differences between groups were calculated with Mann–Whitney U. Linear regression was employed to represent the linear model to predict the dependent variable (BHI) as a function of the independent variable (FSS and subscores). Statistical significance was set at a level of $p < 0.05$.

Results

Fifty consecutive adult patients with primary fibromyalgia syndrome (98% females; median age 54.5 years) were included in the study. Twenty healthy subjects with a median age of 41 years were enrolled as the control group. Demographic data, smoking habit, current therapy, and comorbidities of the studied population are reported in Table 1.

To pursue the hypothesis that FMS was related with an impairment of mitochondrial functionality, we isolated PBMC from the selected population (Table 1) and we evaluated the mitochondrial functionality through the Mito Stress Test. As shown in Fig. 1A, cellular OCR was reduced in patients with FMS following injection of FCCP, an uncoupling agent used to stimulate the respiratory chain at maximum capacity. Correspondingly, maximal respiration was reduced by 27.3% ($p = 0.025$; Fig. 1B) and spare respiratory capacity, being a proxy of cellular flexibility, was significantly lower in patients with primary FMS, i.e., 174.7% (129.2%, 218.0%) compared to controls [195.8% (161.2%, 291.8%); $p = 0.047$; Fig. 1C]. Analyzing key parameters of mitochondrial function by measuring cellular OCR enabled the calculation of the BHI, a dynamic index of bioenergetic health. This parameter was also significantly different between controls (median 1.81; 1.35–1.91; $p = 0.033$) and patients with FMS (median 1.41; 0.85–1.65) (Fig. 1D). No significant differences in mitochondrial parameters were found

	Cohort (n = 50)	Control (n = 20)
AGE (years)		
Median (IQR)	54.5 (51.0–61.0)	41 (31.0–54.0)
Sex		
M, number (%)	1 (2.0)	1 (5.0)
F, number (%)	49 (98.0)	19 (95.0)
Smoker		
Yes, number (%)	3 (6.0)	5 (25.0)
No, number (%)	46 (92.0)	15 (75.0)
Fibromyalgia score		
Total fibromyalgia score, median (IQR)	21 (18–24)	
Widespread Pain Index score, median (IQR)	13 (10–16)	
Symptom Severity Score, median (IQR)	9 (7–10)	
Clinical characteristics		
History of Hashimoto's thyroiditis, number (%)	9 (18)	
Laboratory characteristics		
ANA positivity*, number (%)	11 (22)	
ACPA positivity, number (%)	0 (0)	
RF positivity, number (%)	1 (2)	
ESR, mm/h, median (IQR)	13 (5–21)	

Table 1. Demographic data, smoking habits, current treatments and comorbidities of the studied population. ACPA, anti-citrullinated protein antibodies; ANA, antinuclear antibodies; ESR, Erythrocyte sedimentation rate; F, females; IQR, interquartile range; M, males; RF, rheumatoid factor. *no anti-extractable nuclear antigen (ENA) antibody positivity and no clinical signs and symptoms of connective tissue diseases were present.




Fig. 1. Evaluation of mitochondrial functionality in PBMC of controls and patients with fibromyalgia syndrome (FMS). Panel **A**) shows the oxygen consumption rate (OCR) measured through the Seahorse XF Cell Mito Stress Test. Panel **B**) shows maximal respiration. Panel **C**) shows the spare respiratory capacity (as expressed in %) and panel **D**) the distribution of the BHI. Light grey line and bars represent the control group ($n = 20$), and dark grey line and bars represent patients with FMS ($n = 50$). Yellow dots represent patients with FSS score < 20 , while red dots represent patients with FSS score ≥ 20 . Results are expressed as median (Q1, Q3). Differences between groups were assessed by Mann–Whitney U test, $*p < 0.05$. AA, Antimycin A; BHI, Bioenergetic Health Index; FCCP Carbonyl cyanide-4 (trifluoromethoxy) phenylhydrazone; FMS, Fibromyalgia patients; FSS, Fibromyalgia Severity Score; OCR, Oxygen Consumption Rate; PBMC, peripheral blood mononuclear cells; Rot, rotenone.

in patients with Hashimoto's disease. In patients with positive ANA ($n = 11$), a significantly lower BHI was observed ($p = 0.02$).

As $FSS \geq 20$ indicates a more severe clinical phenotype²⁷, we stratified fibromyalgia patients in two groups with $FSS \geq 20$ and < 20 . As shown in Fig. 2, the lower the BHI and spare respiratory capacity were, the more severe the clinical symptoms. In particular, in the group with $FSS \geq 20$, the spare respiratory capacity was reduced by 23% and the BHI by 19% compared with patients with $FSS < 20$. These differences were statistically different for both variables, respectively, $p = 0.013$ and $p = 0.009$.

Based on these findings, we sought to evaluate the correlation among BHI, spare capacity and the fibromyalgia syndrome, assessed by Spearman correlations. As shown in Fig. 3A–B, we found negative moderate correlations between BHI and FSS ($r = -0.36$) and WPI ($r = -0.38$). A poor negative correlation was instead found between BHI and SSS ($r = -0.1$). The correlations between spare respiratory capacity and FSS and WPI were moderate, $r = -0.31$ and $r = -0.37$, respectively. A poor negative correlation was instead found between spare capacity and SSS ($r = -0.12$).

A subsequent step involved assessing the linear regression between BHI and the FSS, revealing a beta coefficient of -0.39 ($p = 0.005$). Similarly, the linear regression between BHI and WPI yielded a beta of -0.43 ($p = 0.002$). Conversely, the linear regression between BHI and SSS did not show statistical significance (beta -0.07 , ns).

Discussion

The main findings of the present study were twofold. First, we observed that patients suffering from FM exhibited impaired mitochondrial functionality compared to apparent healthy individuals. Among FM patients, those with a severe clinical presentation ($FSS \geq 20$) demonstrated even worse mitochondrial functionality (lower




Fig. 2. Evaluation of mitochondrial functionality in peripheral blood mononuclear cells (PBMC) of patients with fibromyalgia syndrome and a FSS < 20 ($n = 18$) and in the group with FSS ≥ 20 ($n = 32$). Panel A shows the oxygen consumption rate (OCR) measured through the Seahorse XF Cell Mito Stress Test. Panel B indicates the spare respiratory capacity (as expressed in %) and Panel C the distribution of BHI. Orange bars represent the group with FSS < 20 and red bars represent the FSS ≥ 20 group. Results are expressed as median (Q1, Q3). Differences between groups were by Mann–Whitney U test, * $p < 0.05$; ** $p < 0.01$. AA Antimycin A; BHI, Bioenergetic Health Index; FCCP Carbonyl cyanide-4 (trifluoromethoxy) phenylhydrazone; FSS, Fibromyalgia Severity Score; OCR, Oxygen Consumption Rate; PBMCs, peripheral blood mononuclear cells; Rot, rotenone.

BHI). Second, we identified a negative correlation only between BHI and WPI and not between BHI and SSS. The FSS, the score we used to measure FMS severity, is composed by the WPI, reflecting musculoskeletal pain, and SSS, regarding the functional domains (e.g., fatigue, sleep disturbance, cognitive symptoms, headache, abdominal pain or cramps, and depression) that are more linked to the psychological sphere than to the physical sphere. Together with the knowledge that a greater trafficking exists between PBMCs in the circulating blood and mononuclear cells resident in muscles than between PBMCs and mononuclear cells resident in the CNS, we assumed that this finding suggests that mitochondrial activity in PBMCs reflects more specifically the mitochondrial activity of the peripheral tissues than that of CNS.

The choice of evaluating mitochondrial function in PBMCs and using them as a surrogate biomarker to assess fibromyalgia severity can be justified by the following evidence: (a) PBMC mitochondrial respiration correlates with walking speed in older human adults²⁸ and with heart and skeletal muscle mitochondrial function in nonhuman primates²⁹; (b) markers of PBMC mitochondrial content (i.e., PGC1 α , and cytochrome c oxidase subunit IV) appeared to reflect training status in humans³⁰; (c) high levels of mitochondrial reactive oxygen species and low levels of citrate synthase, a mitochondrial matrix protein whose activity correlates with mitochondrial mass, have been described in PBMCs of patients with FMS³¹; (d) when the analysis of




Fig. 3. Correlation analysis between the bioenergetic health index (BHI) vs total fibromyalgia severity score (FSS) (panel **A**); and vs widespread pain index (panel **B**). BHI, bioenergetic health index; WPI, widespread pain index.

mitochondrial function was tested in skin biopsies of fibromyalgia syndrome patients, this was similar to the one detected in PBMCs³²; (e) lipid peroxidation levels, one of the consequences of reactive oxygen species overproduction, are better associated to clinical symptoms in FMS when measured in PBMCs than in plasma³³.

Regarding the hypothesis that assessing mitochondrial function in PBMCs could serve as a surrogate marker of fibromyalgia syndrome severity, our findings align with the literature for similar clinical conditions. Deficits in mitochondrial function have been linked to chronic pain, and approximately 70% of patients with heritable mitochondrial diseases suffer from chronic pain³⁴. Impairment in mitochondrial basal respiration, extracellular acidification rate and ATP-linked OCR have been reported in patients suffering from chronic pain³⁵. Mitochondria play a role in pain resolution. For instance, macrophages can control the resolution of inflammatory pain by transferring mitochondria to sensory neurons³⁶. Proper regulation of mitochondrial activity appears crucial to prevent the transition from acute to chronic pain. Notably, compared to age- and sex-matched controls, PBMCs from fibromyalgia syndrome patients showed significantly lower mitochondrial coupling efficiency. Large-scale proteomics studies revealed altered mitochondrial metabolism, centered on pyruvate dehydrogenase and coenzyme A metabolism, leading to a decreased capacity to provide adequate intracellular ATP levels²⁰.

The importance of mitochondria dysfunctionality in fatigue onset has been further highlighted by the ability to use mitochondrial electron transport chain gene expression to distinguish between individuals with systemic sclerosis and myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) from non-fatigued patients. In this study, the presence of fatigue was associated with a specific gene expression pattern (i.e., reduced expression of mitochondrially encoded genes ND4 and CyB, and increased expression of nuclear gene Cox7C and ND4 and CyB expression). These expression changes were also correlated with disease severity, providing a distinct mitochondrial signature for systemic sclerosis patients with ME/CFS³⁷.

Mitochondrial dysfunction has also been implicated in neuropathic pain. In a murine model induced by chronic constriction injury, various mitochondrial genes and mtDNA copy number were decreased, emphasizing the importance of impaired mitochondrial biogenesis and function in neuropathic pain³⁸.

Furthermore, mitochondrial function may be linked to alterations in neurotransmitter release, including those involved in pain perception. This connection could contribute to the hypersensitivity to pain experienced by patients with fibromyalgia^{39,40}.

Although the relationship between FMS and mitochondrial dysfunction remains an active area of research, accumulating evidence suggests that mitochondrial dysfunction may play a role in the development and maintenance of fibromyalgia symptoms. A recent study showed that a murine model of FMS, characterized by reduced spontaneous locomotor activity and heightened pain sensitivity, showed diminished activity of electron transport chain complexes and citrate synthase, together with decreased mitochondrial biogenesis at the gastrocnemius muscle. These findings support the hypothesis that mitochondrial dysfunction in central nervous system and in skeletal muscles could be an important feature of FMS^{41,42}. Notably, a study investigating muscle energetics performance in a large cohort of older adults found that lower skeletal muscle energetics were associated with more severe performance fatigability⁴³. Interestingly, mitochondria ultrastructural alterations may underlie muscle fatigue. An analysis of murine fibers, particularly the fast-twitch type IIB/IIX fibers prone to fatigue, revealed elongated mitochondrial constrictions in response to fatigue. This effect was accompanied by elevated phosphorylation of Drp1, a key regulator of the fission⁴⁴.

We propose mitochondrial dysfunction, and BHI in particular, as a biomarker of fibromyalgia syndrome severity that may support clinicians in the diagnosis of a disease that is still today underestimated and underdiagnosed also due to the absence of validated biomarkers. The BHI is a metric used to evaluate the overall bioenergetic capacity and efficiency of cells, with a particular focus on mitochondrial function. It is generally calculated using data from Seahorse assays or similar platforms that measure OCR and extracellular acidification rate (ECAR), providing insights into mitochondrial respiration and glycolytic function²⁵. A high

BHI indicates that mitochondria are functioning efficiently and can robustly meet energy demands, while a low BHI may signal mitochondrial dysfunction or stress. This index can be particularly useful in studying diseases linked to mitochondrial dysfunction, such as neurodegenerative diseases, metabolic disorders, and primary mitochondrial diseases⁴⁵. As an additional measure of mitochondrial function in FMS, we showed that the spare respiratory capacity was significantly reduced in patients with FMS.

Mitochondrial dysfunction could serve as a therapeutic target in a disease where pathogenic mechanisms are still unclear, leading to unsatisfactory treatment outcomes. Lastly, since mitochondria are maternally inherited⁴⁶, this aspect warrants further examination to determine a possible correlation with the higher prevalence of the FMS in women.

These results should be interpreted whilst keeping in mind potential limitations. First, the finding of a lower BHI in patients with positive ANA may suggest a role of these antibodies in mitochondrial function impairment. However, this study was not specifically designed to address this point. Therefore, a future study in a dedicated cohort will be designed to respond to this research question. Second, we assumed that FMS patients showed reduced physical activity levels than controls. However, whether the deconditioning in these patients is a cause or a consequence of the mitochondrial dysfunction is still to be elucidated⁴⁷. Finally, as this was a spontaneous clinical research study, the time allocated for each visit, as well as for sample collection and clinical and laboratory assessments, was limited. The collection of data on health-related quality of life, physical activity and sports in a study considering also these aspects, will help clarify this important point.

Conclusions

In our study, we observed impaired mitochondrial function in patients affected with primary fibromyalgia syndrome. Notably, the degree of impairment was more significant in patients with a more severe clinical phenotype and a more evident correlation with musculoskeletal pain was observed. Our findings support the possibility to use the measurement of this imbalance as a biomarker in the diagnosis and follow-up of patients with fibromyalgia syndrome. Our results underscore the need for further investigations in a larger cohort to identify potential biomarkers and treatment targets for this debilitating condition, which significantly impacts quality of life and currently lacks specific etiopathogenic treatments.

Data availability

The datasets used and/or analysed during the current study available from the corresponding author on request.

Received: 28 June 2024; Accepted: 26 November 2024

Published online: 04 December 2024

References

1. Clauw, D. J. Fibromyalgia: A clinical review. *JAMA*. **311**(15), 1547–1555 (2014).
2. Wolfe, F. et al. The American college of rheumatology 1990 criteria for the classification of fibromyalgia. Report of the multicenter criteria committee. *Arthritis Rheum.* **33**(2), 160–172 (1990).
3. Wolfe, F. et al. 2016 Revisions to the 2010/2011 fibromyalgia diagnostic criteria. *Semin. Arthritis Rheum.* **46**(3), 319–329 (2016).
4. Vincent, A. et al. Prevalence of fibromyalgia: A population-based study in Olmsted county, Minnesota, utilizing the rochester epidemiology project. *Arthritis Care Res. (Hoboken)*. **65**(5), 786–792 (2013).
5. McBeth, J. & Jones, K. Epidemiology of chronic musculoskeletal pain. *Best Pract. Res. Clin. Rheumatol.* **21**(3), 403–425 (2007).
6. White, K. P., Speechley, M., Harth, M. & Ostbye, T. The London fibromyalgia epidemiology study: the prevalence of fibromyalgia syndrome in London. *Ontario. J. Rheumatol.* **26**(7), 1570–1576 (1999).
7. Choy, E. et al. A patient survey of the impact of fibromyalgia and the journey to diagnosis. *BMC Health Serv. Res.* **10**, 102 (2010).
8. Sarzi-Puttini, P., Giorgi, V., Marotto, D. & Atzeni, F. Fibromyalgia: An update on clinical characteristics, aetiopathogenesis and treatment. *Nat. Rev. Rheumatol.* **16**(11), 645–660 (2020).
9. Ghavidel-Parsa, B. & Bidari, A. The crosstalk of the pathophysiologic models in fibromyalgia. *Clin. Rheumatol.* **42**(12), 3177–3187 (2023).
10. Woolf, C. J. Central sensitization: implications for the diagnosis and treatment of pain. *Pain* **152**(3 Suppl), S2–s15 (2011).
11. Wolfe, F. & Rasker, J. J. The evolution of fibromyalgia, its concepts, and criteria. *Cureus*. **13**(11), e20010 (2021).
12. Harrington, J. S., Ryter, S. W., Plataki, M., Price, D. R. & Choi, A. M. K. Mitochondria in health, disease, and aging. *Physiol. Rev.* **103**(4), 2349–2422 (2023).
13. Brum, E. D. S. et al. Relevance of mitochondrial dysfunction in the reserpine-induced experimental fibromyalgia model. *Mol. Neurobiol.* **57**(10), 4202–4217 (2020).
14. Favero, G., Bonomini, F., Franco, C., Rezzani, R. Mitochondrial dysfunction in skeletal muscle of a fibromyalgia model: The potential benefits of melatonin. *Int. J. Mol. Sci.* **20**(3), (2019).
15. Gerdle, B. et al. Decreased muscle concentrations of ATP and PCR in the quadriceps muscle of fibromyalgia patients—a 31P-MRS study. *Eur. J. Pain.* **17**(8), 1205–1215 (2013).
16. Da Rosa, P. C., Bertomeu, J. B., Royes, L. F. F. & Osiecki, R. The physical exercise-induced oxidative/inflammatory response in peripheral blood mononuclear cells: Signaling cellular energetic stress situations. *Life Sci.* **321**, 121440 (2023).
17. Hedges, C. P. et al. Peripheral blood mononuclear cells do not reflect skeletal muscle mitochondrial function or adaptation to high-intensity interval training in healthy young men. *J. Appl. Physiol.* **126**(2), 454–461 (2019).
18. Gorman, G. S. et al. Perceived fatigue is highly prevalent and debilitating in patients with mitochondrial disease. *Neuromuscul. Disord.* **25**(7), 563–566 (2015).
19. Israel, L. et al. Mitochondrial structural alterations in fibromyalgia: A pilot electron microscopy study. *Clin. Exp. Rheumatol.* **42**(6), 1215–1223 (2024).
20. Wolfe, F. Pain extent and diagnosis: development and validation of the regional pain scale in 12,799 patients with rheumatic disease. *J. Rheumatol.* **30**(2), 369–378 (2003).
21. Audano, M., Pedretti, S., Cermenati, G., Brioschi, E., Diaferia, G. R., Ghisletti, S., et al. Zc3h10 is a novel mitochondrial regulator. *EMBO Rep.* **19**(4), (2018).
22. Macchi, C. et al. Monocarboxylate transporter 1 deficiency impacts CD8(+) T lymphocytes proliferation and recruitment to adipose tissue during obesity. *iScience* **25**(6), 104435 (2022).
23. Ehinger, J. K. et al. Mitochondrial function in peripheral blood cells across the human lifespan. *NPJ Aging*. **10**(1), 10 (2024).

24. Greco, M. F., Rizzuto, A. S., Zarà, M., Cafora, M., Favero, C., Solazzo, G., et al. PCSK9 confers inflammatory properties to extracellular vesicles released by vascular smooth muscle cells. *Int J Mol Sci.* **23**(21), (2022).
25. Chacko, B. K. et al. The bioenergetic health index: A new concept in mitochondrial translational research. *Clin Sci (Lond).* **127**(6), 367–373 (2014).
26. Rosner, B. *Fundamentals of biostatistics*. 7th ed. Boston: Brooks/Cole, Cengage Learning; (2011).
27. Wolfe, F., Walitt, B. T., Rasker, J. J., Katz, R. S. & Häuser, W. The use of polysymptomatic distress categories in the evaluation of fibromyalgia (FM) and FM severity. *J. Rheumatol.* **42**(8), 1494–1501 (2015).
28. Tyrrell, D. J. et al. Respirometric profiling of muscle mitochondria and blood cells are associated with differences in gait speed among community-dwelling older adults. *J. Gerontol. A Biol. Sci. Med. Sci.* **70**(11), 1394–1399 (2015).
29. Tyrrell, D. J., Bharadwaj, M. S., Jorgensen, M. J., Register, T. C. & Molina, A. J. Blood cell respirometry is associated with skeletal and cardiac muscle bioenergetics: Implications for a minimally invasive biomarker of mitochondrial health. *Redox. Biol.* **10**, 65–77 (2016).
30. Busquets-Cortés, C. et al. Training and acute exercise modulates mitochondrial dynamics in football players' blood mononuclear cells. *Eur. J. Appl. Physiol.* **117**(10), 1977–1987 (2017).
31. Cordero, M. D. et al. Mitochondrial dysfunction and mitophagy activation in blood mononuclear cells of fibromyalgia patients: Implications in the pathogenesis of the disease. *Arthritis. Res. Ther.* **12**(1), R17 (2010).
32. Cordero, M. D. et al. Mitochondrial dysfunction in skin biopsies and blood mononuclear cells from two cases of fibromyalgia patients. *Clin. Biochem.* **43**(13–14), 1174–1176 (2010).
33. Cordero, M. D. et al. Clinical symptoms in fibromyalgia are better associated to lipid peroxidation levels in blood mononuclear cells rather than in plasma. *PLoS One.* **6**(10), e26915 (2011).
34. van den Ameel, J. et al. Chronic pain is common in mitochondrial disease. *Neuromuscul. Disord.* **30**(5), 413–419 (2020).
35. Chelimsky, G. et al. Impaired mitochondrial bioenergetics function in pediatric chronic overlapping pain conditions with functional gastrointestinal disorders. *Pain Res. Manag.* **2021**, 6627864 (2021).
36. van der Vlist, M. et al. Macrophages transfer mitochondria to sensory neurons to resolve inflammatory pain. *Neuron.* **110**(4), 613–26.e9 (2022).
37. van Eeden, C., Redmond, D., Mohazab, N., Larché, M. J., Mason, A. L., Cohen Tervaert, J. W., et al. Evidence of a Novel Mitochondrial Signature in Systemic Sclerosis Patients with Chronic Fatigue Syndrome. *Int. J. Mol. Sci.* **24**(15), (2023).
38. Sun, J. et al. Nrf2 activation attenuates chronic constriction injury-induced neuropathic pain via Induction of PGC-1 α -mediated mitochondrial biogenesis in the spinal cord. *Oxid. Med. Cell Longev.* **2021**, 9577874 (2021).
39. Ivannikov, M. V., Sugimori, M. & Llinás, R. R. Synaptic vesicle exocytosis in hippocampal synaptosomes correlates directly with total mitochondrial volume. *J. Mol. Neurosci.* **49**(1), 223–230 (2013).
40. Duarte, F. V., Ciampi, D. & Duarte, C. B. Mitochondria as central hubs in synaptic modulation. *Cell Mol. Life Sci.* **80**(6), 173 (2023).
41. Inferriera, F. et al. Impaired mitochondrial quality control in fibromyalgia: Mechanisms involved in skeletal muscle alteration. *Arch Biochem Biophys.* **758**, 110083 (2024).
42. Marino, Y. et al. Role of mitochondrial dysfunction and biogenesis in fibromyalgia syndrome: Molecular mechanism in central nervous system. *Biochim. Biophys. Acta Mol. Basis. Dis.* **1870**(7), 167301 (2024).
43. Qiao, Y. S., Santanasto, A. J., Coen, P. M., Cawthon, P. M., Cummings, S. R., Forman, D. E., et al. Associations between skeletal muscle energetics and accelerometry-based performance fatigability: Study of muscle, mobility and aging. *Aging Cell.* e14015, (2023).
44. Lavorato, M., Loro, E., Debattisti, V., Khurana, T. S., Franzini-Armstrong, C. Elongated mitochondrial constrictions and fission in muscle fatigue. *J. Cell Sci.* **131**(23), (2018).
45. Koklesova, L. et al. Mitochondrial health quality control: Measurements and interpretation in the framework of predictive, preventive, and personalized medicine. *EPMA J.* **13**(2), 177–193 (2022).
46. Lee, W. et al. Molecular basis for maternal inheritance of human mitochondrial DNA. *Nat Genet.* **55**(10), 1632–1639 (2023).
47. Martínez-Lara, A. et al. Mitochondrial imbalance as a new approach to the study of fibromyalgia. *Open Access Rheumatol.* **12**, 175–185 (2020).

Acknowledgements

S. P. was supported by Fondazione Umberto Veronesi. We thank the patients for participating in this study.

Author contributions

CM, MR and RG conceived the study, analyzed the data and wrote the manuscript. CM, AG, IF, SL, SP performed the experiments and the analyses. NM and AC contributed to data interpretation and revised the manuscript. All authors provided critical feedback on drafts and approved the final manuscript.

Fundings

This study was partially supported by the Italian Ministry of Health—Bando Ricerca Corrente (2024 to RG), by Banca d'Italia (2023 to MR), by Associazione Italiana Sindrome Fibromialgica (AISF ODV to RG and MR), by the European Union MSCA Doctoral Networks Grant Number 101167421 (to MR and CM), by Progetto Eccellenza (2023–2027) to the Department of Pharmacological and Biomolecular Sciences “Rodolfo Paoletti,” Università degli Studi di Milano, and by the Italian Ministry of Health with Ricerca Corrente and “5xmille” funds to N.M.

Declarations

Competing interests

The authors declare no competing interests.

Additional information

Correspondence and requests for materials should be addressed to M.R. or R.G.

Reprints and permissions information is available at www.nature.com/reprints.

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by-nc-nd/4.0/>.

© The Author(s) 2024